Amgen, Inc. (AMGN) Shares Sold by Carroll Financial Associates Inc.
Carroll Financial Associates Inc. lessened its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 6.2% during the fourth quarter, HoldingsChannel reports. The firm owned 6,732 shares of the medical research company’s stock after selling 442 shares during the period. Carroll Financial Associates Inc.’s holdings in Amgen were worth $1,170,000 as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in AMGN. Janus Henderson Group PLC boosted its position in shares of Amgen by 3,664.7% during the 2nd quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock worth $637,139,000 after purchasing an additional 3,601,087 shares in the last quarter. FMR LLC raised its holdings in shares of Amgen by 4.8% in the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after acquiring an additional 2,587,041 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Amgen by 40.9% in the 2nd quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock worth $585,607,000 after acquiring an additional 986,700 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Amgen by 1.9% in the 2nd quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock worth $8,516,980,000 after acquiring an additional 909,689 shares during the last quarter. Finally, Nordea Investment Management AB raised its holdings in shares of Amgen by 12.9% in the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after acquiring an additional 806,119 shares during the last quarter. 78.03% of the stock is currently owned by institutional investors.
Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $182.45 on Friday. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17. The company has a market cap of $131,452.16, a PE ratio of 14.50, a price-to-earnings-growth ratio of 2.18 and a beta of 1.42. Amgen, Inc. has a one year low of $152.16 and a one year high of $201.23.
Amgen announced that its Board of Directors has initiated a stock buyback program on Thursday, February 1st that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the medical research company to buy shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be paid a dividend of $1.32 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.28 annualized dividend and a dividend yield of 2.89%. This is a positive change from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio (DPR) is presently 205.45%.
In other news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $176.83, for a total transaction of $269,665.75. Following the completion of the sale, the executive vice president now owns 56,106 shares in the company, valued at approximately $9,921,223.98. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 4,575 shares of company stock valued at $818,361. 0.19% of the stock is currently owned by company insiders.
A number of equities research analysts recently weighed in on the stock. Mizuho upped their target price on shares of Amgen from $192.00 to $200.00 and gave the stock a “buy” rating in a report on Monday, February 12th. Leerink Swann restated a “market perform” rating on shares of Amgen in a report on Friday, February 2nd. Morgan Stanley lowered their target price on shares of Amgen from $204.00 to $196.00 and set an “overweight” rating on the stock in a report on Friday, February 2nd. Zacks Investment Research lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Royal Bank of Canada lowered their target price on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating on the stock in a report on Thursday, October 26th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $191.84.
COPYRIGHT VIOLATION NOTICE: This article was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://theolympiareport.com/2018/02/23/amgen-inc-amgn-shares-sold-by-carroll-financial-associates-inc.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.